Related Experiment Videos
[Clinical studies of cefotiam in otorhinolaryngologic infections]
Abstract:
Cefotiam (CTM) was intravenously or intramuscularly given to 14 patients with infections in the field of otorhinolaryngology including 5 cases with chronic suppurative otitis media. Daily doses of CTM were 1 to 3 g and its administration period was 3 to 10 days. Clinical responses were excellent in 1 patient, good in 8, fair in 2 and poor in 3, the rate of satisfactory clinical responses (excellent and good) being 64.3% (9/14). Staphylococci were most frequently isolated from the clinical materials. As for side effects, elevation of GOT and GPT was observed in 1 patient.
Insights
Cefotiam (CTM) effectively treated otorhinolaryngology infections in 64.3% of patients. This antibiotic showed promise against Staphylococci, with minimal side effects observed in clinical trials.
Area of Science:
- Pharmacology
- Infectious Diseases
- Otorhinolaryngology
Context:
- Cefotiam (CTM) is a cephalosporin antibiotic.
- Otorhinolaryngology infections, including chronic suppurative otitis media, pose significant clinical challenges.
- Evaluating novel therapeutic options is crucial for improving patient outcomes.
Purpose:
- To assess the clinical efficacy and safety of Cefotiam (CTM) in patients with otorhinolaryngology infections.
- To determine the effectiveness of CTM against frequently isolated pathogens, particularly Staphylococci.
- To document any adverse effects associated with CTM administration in this patient cohort.
Summary:
- Cefotiam (CTM) was administered intravenously or intramuscularly to 14 patients with otorhinolaryngology infections at daily doses of 1-3 g for 3-10 days.
- A satisfactory clinical response (excellent or good) was observed in 64.3% (9/14) of patients.
- Staphylococci were the most common isolates. One patient experienced elevated GOT and GPT levels, indicating a potential side effect.
Impact:
- Cefotiam (CTM) demonstrates significant clinical efficacy in treating otorhinolaryngology infections.
- The findings support the use of Cefotiam (CTM) as a viable treatment option for Staphylococcal infections in this region.
- Further research may explore CTM's role in managing antibiotic-resistant strains and optimizing treatment protocols.